Published in QJM on January 21, 2011
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Cancer-associated bone disease. Osteoporos Int (2013) 0.94
The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int (2013) 0.80
Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women. Osteoporos Int (2011) 0.79
Clinical utility of denosumab for treatment of bone loss in men and women. Clin Interv Aging (2011) 0.79
Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study. Osteoporos Int (2015) 0.79
Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women. Osteoporos Int (2014) 0.78
Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis. Int J Womens Health (2014) 0.76
Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. Clinicoecon Outcomes Res (2015) 0.75
Impairment of cold injury-induced muscle regeneration in mice receiving a combination of bone fracture and alendronate treatment. PLoS One (2017) 0.75